Explicit hypoxia targeting with tumor suppression by creating an “obligate” anaerobic Salmonella Typhimurium strain
Open Access
- 1 June 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 2 (1), 436
- https://doi.org/10.1038/srep00436
Abstract
Using bacteria as therapeutic agents against solid tumors is emerging as an area of great potential in the treatment of cancer. Obligate and facultative anaerobic bacteria have been shown to infiltrate the hypoxic regions of solid tumors, thereby reducing their growth rate or causing regression. However, a major challenge for bacterial therapy of cancer with facultative anaerobes is avoiding damage to normal tissues. Consequently the virulence of bacteria must be adequately attenuated for therapeutic use. By placing an essential gene under a hypoxia conditioned promoter, Salmonella Typhimurium strain SL7207 was engineered to survive only in anaerobic conditions (strain YB1) without otherwise affecting its functions. In breast tumor bearing nude mice, YB1 grew within the tumor, retarding its growth, while being rapidly eliminated from normal tissues. YB1 provides a safe bacterial vector for anti-tumor therapies without compromising the other functions or tumor fitness of the bacterium as attenuation methods normally do.Keywords
This publication has 47 references indexed in Scilit:
- A method to generate recombinant Salmonella typhi Ty21a strains expressing multiple heterologous genes using an improved recombineering strategyApplied Microbiology and Biotechnology, 2011
- Containment of Tumor-Colonizing Bacteria by Host NeutrophilsCancer Research, 2008
- Influence of the Environment on the [4Fe−4S]2+ to [2Fe−2S]2+ Cluster Switch in the Transcriptional Regulator FNRJournal of the American Chemical Society, 2008
- Clostridial spores as live 'Trojan horse' vectors for cancer gene therapy: comparison with viral delivery systemsGenetic Vaccines and Therapy, 2008
- Oral delivery of tumor‐targeting Salmonella for cancer therapy in murine tumor modelsCancer Science, 2007
- Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumoursEuropean Journal of Cancer, 2007
- Genetically engineered Bifidobacterium longum for tumor‐targeting enzyme‐prodrug therapy of autochthonous mammary tumors in ratsCancer Science, 2006
- Exploiting tumour hypoxia in cancer treatmentNature Reviews Cancer, 2004
- Continuous Intravenous Administration of Live Genetically Modified Salmonella Typhimurium in Patients With Metastatic MelanomaJournal of Immunotherapy, 2003
- Biodistribution and Genetic Stability of the Novel Antitumor Agent VNP20009, a Genetically Modified Strain ofSalmonella typhimuriumThe Journal of Infectious Diseases, 2000